BioSpace News Archive

Laekna Therapeutics, a clinical-stage global biotechnology company，announced the appointment of Jeff Porter, Ph.D. as the Chairman of its Scientific Advisory Board.

VolitionRx Limited, a multi-national epigenetics company, has announced the signing of an exclusive global supply and licensing agreement with Heska Corporation to sell its Nu.Q® Vet Cancer Screening Test at the point of care for companion animals.

Sumitomo Dainippon Pharma Oncology, Inc., today announced that the first patient has been dosed in the Phase 1/2 study of DSP-5336, an inhibitor of menin binding to mixed-lineage leukemia (MLL) protein, in patients with relapsed or refractory acute myeloid leukemia (AML) or acute lymphocytic leukemia (ALL).

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Reshma Rangwala, MD, PhD, as the Company’s Chief Medical Officer.

ShouTi Inc., a clinical-stage global biopharmaceutical company developing novel oral therapeutics to treat a wide range of chronic diseases, announced the appointment of Sharon Tetlow to the company’s board of directors.

Shorla Oncology (‘Shorla’), an Irish specialty pharmaceutical company, today announced the appointment of Dennis Purcell as Board Chairman.

Fortis Life Sciences today announced it is the exclusive channel partner for AccuGenomics in the Unites States, with co-exclusive rights in Europe.

Australian biotech company Noxopharm (ASX:NOX) has announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to Veyonda ® , its lead oncology drug candidate , for use in the treatment of soft tissue sarcoma.

Cybin Announces Successful Completion of In Vivo Preclinical Studies for its Deuterated Psilocybin Analog CYB003 Supporting Advancement into Phase 1/2a Clinical Trial

VBI Vaccines Inc. today announced that PreHevbrio™ [Hepatitis B Vaccine (Recombinant)] is now available in the United States for the prevention of infection caused by all known subtypes of hepatitis B virus (HBV) in adults age 18 years and older.